{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:13:29Z","timestamp":1789456409993,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004503","name":"Benha University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004503","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00417-026-07211-6","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:18:26Z","timestamp":1776410306000},"page":"2889-2897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the efficacy and safety of brolucizumab versus aflibercept on visual and anatomical outcomes in diabetic macular edema: a retrospective comparative study"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-9616","authenticated-orcid":false,"given":"Ehab Mohamed Elsayed","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa Kamel Abdelmoneim","family":"Abdelmaged","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif A.","family":"Dabour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abdelshafy","family":"Tabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"7211_CR1","unstructured":"Ko S (2023) Productivity loss among patients with diabetic macular edema in two eyes: a retrospective commercial claims analysis in the United States. University of Washington"},{"key":"7211_CR2","doi-asserted-by":"publisher","unstructured":"Hachana S, Larriv\u00e9e B (2022) TGF-\u03b2 Superfamily Signaling in the Eye: Implications for Ocular Pathologies. Cells Jul 29(15). https:\/\/doi.org\/10.3390\/cells11152336","DOI":"10.3390\/cells11152336"},{"issue":"7","key":"7211_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s13300-023-01410-8","volume":"14","author":"S Sydnor","year":"2023","unstructured":"Sydnor S, Chatterjee S, Cooney P et al (2023) Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis. Diabetes Ther Jul 14(7):1193\u20131216. https:\/\/doi.org\/10.1007\/s13300-023-01410-8","journal-title":"Diabetes Ther Jul"},{"key":"7211_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Emanuelli A, Bandello F et al (2022) KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol Jun 238:157\u2013172. https:\/\/doi.org\/10.1016\/j.ajo.2022.01.004","journal-title":"Am J Ophthalmol Jun"},{"key":"7211_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","volume":"260","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Garweg JG, Regillo C et al (2024) KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol Apr 260:70\u201383. https:\/\/doi.org\/10.1016\/j.ajo.2023.07.012","journal-title":"Am J Ophthalmol Apr"},{"issue":"4","key":"7211_CR6","doi-asserted-by":"publisher","first-page":"99235","DOI":"10.5493\/wjem.v14.i4.99235","volume":"20","author":"A Arora","year":"2024","unstructured":"Arora A, Morya AK, Gupta PC, Menia NK, Nishant P, Gupta V (2024) Intravitreal therapy for the management of diabetic retinopathy: A concise review. World J Exp Med Dec 20(4):99235. https:\/\/doi.org\/10.5493\/wjem.v14.i4.99235","journal-title":"World J Exp Med Dec"},{"issue":"2","key":"7211_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41433-021-01816-3","volume":"36","author":"D Chakraborty","year":"2022","unstructured":"Chakraborty D, Mondal S, Parachuri N, Kumar N, Sharma A (2022) Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema. Eye (Lond) Feb 36(2):358\u2013360. https:\/\/doi.org\/10.1038\/s41433-021-01816-3","journal-title":"Eye (Lond) Feb"},{"issue":"4","key":"7211_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/08820538.2023.2271095","volume":"39","author":"H Abu Serhan","year":"2024","unstructured":"Abu Serhan H, Taha MJJ, Abuawwad MT et al (2024) Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Semin Ophthalmol May 39(4):251\u2013260. https:\/\/doi.org\/10.1080\/08820538.2023.2271095","journal-title":"Semin Ophthalmol May"},{"issue":"1","key":"7211_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","volume":"1","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Zarbin MA, Barakat MR et al (2022) Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol Jan 1(1):20\u201328. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.4585","journal-title":"JAMA Ophthalmol Jan"},{"key":"7211_CR10","doi-asserted-by":"publisher","unstructured":"Radke NV, Mohamed S, Brown RB et al (2023) Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data. Asia Pac J Ophthalmol (Phila) 12(2):168\u2013183. https:\/\/doi.org\/10.1097\/apo.0000000000000602","DOI":"10.1097\/apo.0000000000000602"},{"issue":"1","key":"7211_CR11","doi-asserted-by":"publisher","first-page":"e52176","DOI":"10.7759\/cureus.52176","volume":"16","author":"F Bragan\u00e7a","year":"2024","unstructured":"Bragan\u00e7a F, Ferreira A, Leite J et al (2024) Real-World Experience With Brolucizumab 6\u00a0mg for Diabetic Macular Edema. Cureus Jan 16(1):e52176. https:\/\/doi.org\/10.7759\/cureus.52176","journal-title":"Cureus Jan"},{"key":"7211_CR12","doi-asserted-by":"publisher","unstructured":"R\u00fcbsam A, H\u00f6ssl L, Rau S, B\u00f6ker A, Zeitz O, Joussen AM (2024) Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Na\u00efve and Therapy-Refractory Patients with Diabetic Macular Edema. J Clin Med Mar 21(6). https:\/\/doi.org\/10.3390\/jcm13061819","DOI":"10.3390\/jcm13061819"},{"key":"7211_CR13","unstructured":"Charters L Brolucizumab shows promise over aflibercept for diabetic macular edema in meta-analysis"},{"issue":"3","key":"7211_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/11206721231207459","volume":"34","author":"TR Elhamaky","year":"2024","unstructured":"Elhamaky TR (2024) Comparison between intravitreal brolucizumab and aflibercept in the treatment-naive central involved diabetic macular edema: One-year real-life case series. Eur J Ophthalmol May 34(3):797\u2013802. https:\/\/doi.org\/10.1177\/11206721231207459","journal-title":"Eur J Ophthalmol May"},{"key":"7211_CR15","doi-asserted-by":"publisher","first-page":"102152","DOI":"10.1016\/j.ajoc.2024.102152","volume":"36","author":"D Chakraborty","year":"2024","unstructured":"Chakraborty D, Sharma A, Mondal S et al (2024) Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study. Am J Ophthalmol Case Rep Dec 36:102152. https:\/\/doi.org\/10.1016\/j.ajoc.2024.102152","journal-title":"Am J Ophthalmol Case Rep Dec"},{"issue":"12","key":"7211_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","volume":"1","author":"RP Singh","year":"2023","unstructured":"Singh RP, Barakat MR, Ip MS et al (2023) Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol Dec 1(12):1152\u20131160. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.5248","journal-title":"JAMA Ophthalmol Dec"},{"issue":"6","key":"7211_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.18553\/jmcp.2021.27.6.743","volume":"27","author":"JS Yu","year":"2021","unstructured":"Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC (2021) Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm Jun 27(6):743\u2013752. https:\/\/doi.org\/10.18553\/jmcp.2021.27.6.743","journal-title":"J Manag Care Spec Pharm Jun"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07211-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07211-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07211-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:53:44Z","timestamp":1789455224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07211-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7211"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07211-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Benha University\u2019s Faculty of Medicine examined and approved the study protocol (Approval Code: Rc 5_1_2025). In compliance with national and institutional ethical guidelines for retrospective research, the need for formal informed permission was not required. To protect participant confidentiality, all data were completely anonymised before analysis. The requirement for informed consent was waived by the Institutional Review Board (IRB) of the Faculty of Medicine, Benha University, in accordance with national regulations for retrospective research.NCT07096713 was the study\u2019s registration number on ClinicalTrials.gov.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}